Equities Analysts Set Expectations for SNDX Q1 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Equities research analysts at B. Riley issued their Q1 2025 earnings estimates for Syndax Pharmaceuticals in a report released on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings per share of ($1.11) for the quarter. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals’ Q2 2025 earnings at ($1.11) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million.

SNDX has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday. StockNews.com downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday. Scotiabank decreased their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, Citigroup decreased their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Syndax Pharmaceuticals Trading Down 7.1 %

NASDAQ:SNDX opened at $14.38 on Wednesday. Syndax Pharmaceuticals has a 12 month low of $12.06 and a 12 month high of $25.16. The firm has a fifty day simple moving average of $14.26 and a 200-day simple moving average of $16.71. The company has a market capitalization of $1.23 billion, a P/E ratio of -3.96 and a beta of 0.90.

Insider Transactions at Syndax Pharmaceuticals

In related news, CFO Keith A. Goldan sold 3,777 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the sale, the chief financial officer now owns 90,746 shares in the company, valued at $1,406,563. This trade represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Neil Gallagher sold 4,618 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the transaction, the insider now owns 85,095 shares of the company’s stock, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,683 shares of company stock worth $336,087. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd purchased a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth about $26,000. Quantbot Technologies LP acquired a new position in Syndax Pharmaceuticals during the third quarter valued at approximately $49,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares in the last quarter. Virtus ETF Advisers LLC lifted its position in Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after buying an additional 827 shares in the last quarter. Finally, Cape Investment Advisory Inc. lifted its position in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after purchasing an additional 3,927 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).